5000th protein structure at BESSY II: Starting point for a COVID drug
The structure shows the main domain of the non-structural protein 1 (Nsp1) of SARS-CoV-2. A small molecule from the fragment library has docked in one of its pockets. This molecule could serve as a starting point for the development of antiviral drugs. © HZB
Many proteins have a complex architecture that enables biological functions. Molecules can bind to specific sites on a protein and alter its function. A team at HZB has now investigated the Nsp1 protein, which plays a role in infection with the SARS-CoV-2 virus. They analysed protein crystals, previously mixed with molecules from a fragment library, and discovered a total of 21 candidates as starting points for drug development. At the same time, they also decoded the 5000th structure at BESSY II.
Even after the global pandemic caused by the SARS-CoV-2 virus has subsided, many variants are still circulating around the world, and the search for effective drugs continues. A team at HZB investigated the main domain of the so-called Nsp1 protein, which plays a role in SARS-CoV-2 infection. The Nsp1 protein blocks the production of the host cell's own proteins in the ribosomes of the host cells, thereby hindering the defence against the SARS-CoV-2 virus. Therefore, the main domain of Nsp1 is considered a promising target for the development of antiviral drugs.
The MX team at BESSY II conducted a high-throughput experiment with a fragment library. This fragment library consists of hundreds of small molecules, each of which was mixed individually with crystals of the Nsp1 protein. The crystals were then measured at the MX beamlines of BESSY II and their respective three-dimensional structures were determined. The results showed that 21 of these molecules were able to bind to the main domain of Nsp1. Many of these fragments, including the one shown in the 5000th structure, docked deep into a pocket of Nsp1 located near a functionally important region. ‘This makes it a promising starting point for the development of larger drug molecules that can disrupt Nsp1 during the replication of SARS-CoV-2,’ says Dr Frank Lennartz, first author of the study.
‘Fragment screening allows us to systematically test small chemical building blocks and determine which of them bind to specific sites on the protein. This reveals where the protein is vulnerable and at the same time provides starting blocks from which complex active substances can be developed,’ says Dr Manfred Weiss, head of Macromolecular Crystallography at HZB.
- Surprising insights into the chemistry of hydroxyl radicals at BESSY IIHow do radicals form in aqueous solutions when exposed to UV light? This question is important for health research and environmental protection, for example with regard to the overfertilisation of water bodies by intensive agriculture. A team at BESSY II has now developed a new method of investigating hydroxyl radicals in solution. By using a clever trick, the scientists gained surprising insights into the reaction pathway.
- AI-driven Catalyst Discovery: €30 million funding for German consortiumSix partners from research and industry, including Helmholtz-Zentrum Berlin (HZB), the Fritz-Haber-Institute of the Max Planck Society (FHI), BASF, Dunia Innovations, Siemens Energy, and the Technical University Berlin are launching a joint project to accelerate the catalyst discovery. The German Federal Ministry for Science, Technology and Space (BMFTR) is providing €30 million in funding for ASCEND (Accelerated Solutions for Catalysis using Emerging Nanotechnology and Digital Innovation). The research initiative targets the defossilisation of energy-intensive industries while safeguarding industrial competitiveness, with a focus on the chemical sector. The five-year project will start on 1st April 2026.
- Catalysis research at HZB gets new facilityAs part of the CatLab project, HZB has acquired a unique facility for measuring the catalytic performance of thin-film catalysts. Built by ILS in Adlershof, it has now been delivered. The facility consists of a total of eight chemical reactors in which catalytic systems can be tested. At over €2.5 million, this is the largest single investment in the CatLab project.